Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function

Internal Medicine

Volumn 48, Issue 1, 2009, Pages 11-17

  Koda, Masahiko ^a   Nagahara, Takakazu ^a   Matono, Tomomitu ^a   Sugihara, Takaaki ^a   Mandai, Mari ^a   Ueki, Masaru ^a   Ohyama, Kenji ^a   Hosho, Keiko ^a   Okano, Junichi ^a   Kishimoto, Yukihiro ^b   Kono, Michimori ^c   Maruyama, Shigeo ^d   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b SAN IN ROSAI HOSPITAL   (Japan)

^c Matsue City Hospital   (Japan)

^d Maruyama Clinic   (Japan)

Author keywords

HBV; Hepatocellular carcinoma; Nucleotide analog; Survival rate

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL RATE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEOTIDES; SURVIVAL RATE;

EID: 61749100341     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1534     Document Type: Article

References (23)

1. Ganem D, Prince AM. Hepatitis B virus infection-Natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004.
2. Pungpapong S, Kim WR, Potterucha JJ. Natural history of hepatitis B virus infection: An update for clinicians. Mayo Clin Proc 82: 967-975, 2007.
3. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32: 294-298, 1991.
4. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 97: 265-272, 2005.
5. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis 26: 142-152, 2006.
6. The Liver Cancer Study Group of Japan. Classification of primary liver cancer. 2nd English ed. Kanehara Press, Tokyo, 2003.
7. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207, 2003.
8. Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg 192: 29-33, 2006.
9. Kawano Y, Sasaki A, Kai S, et al. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: A retrospective study. Eur J Surg Oncol 2008 (e-pub).
10. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. Cancer 103: 1201-1209, 2005.
11. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 39: 919-926, 2004.
12. Wu FS, Zhao WH, Liang TB, et al. Survival factors after resection of small hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4: 379-384, 2005.
13. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124: 105-117, 2003.
14. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10: 431-439, 2005.
15. Akuta N, Suzuki F, Suzuki Y, et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study. J Med Virol 75: 491-498, 2005.
16. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45: 1056-1075, 2007.
17. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531, 2004.
18. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 32: 173-184, 2005.
19. Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatrocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 59: 217-224, 2005.
20. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 22: 1929-1935, 2007.
21. Huang Y, Wang Z, An S, et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 80: 591-597, 2008.
22. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
23. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30: 567-572, 1999.